THE MAYO CLINIC ORGANIZED INTERNATIONAL CONSENSUS DEVELOPMENT MEETING ON EPSTEIN BARR

Epstein-Barr virus-induced posttransplant lympho-proliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogene-sis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the preven-tion and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This re-view summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for fu-ture areas of study. The term Epstein-Barr virus- (EBV*) induced posttrans